Pathway Genomics Debuts First Genomic Wellness App Powered by IBM Watson

LAS VEGAS 7 January 2016 – Pathway Genomics and IBM (NYSE: IBM) today unveiled at the Digital Health Summit at CES 2016 the closed-alpha release of Pathway Genomics OME™ app, powered by Watson. The Pathway Genomics OME app merges cognitive computing and deep learning with precision medicine and genetics to enable Pathway Genomics to provide consumers with personalized wellness information.

This alpha version of the app incorporates information from Pathway’s “FIT” Test — a wellness-based diet, exercise, and metabolism report compiled with information from the users unique genetic traits, as well as their health habits, data from GPS and wearable health monitors in addition to information from the users Apple HealthKit. Future versions of Pathway’s OME will enable users to opt-in to include electronic health records, insurance information, and additional datasets that will enable OME to provide precise and actionable wellness recommendations.

Pathway Genomics Corporation Raises Over $40 Million In Series E Financing

SAN DIEGO, CA – January 5, 2016 – Pathway Genomics Corporation, a global precision medicine company with mobile health solutions, today announced it has successfully raised over $40 million in a Series E financing.

This brings the total investment into Pathway Genomics to over $130 million. Investors in this round of funding include IBM Watson, Pathway’s partner in the development of a mobile health application using artificial intelligence to provide personalized health and wellness guidance.

Pathway Genomics Announces Definitive Settlement With United States

Pathway Genomics has reached a settlement with the United States Department of Justice. Pathway admits no wrongdoing as part of the settlement and is neither an admission of liability or wrongdoing by the Company, nor a concession by the United States that its claims are not well founded.

Pathway Genomics’ Response to FDA Letter on CancerIntercept™ Detect

Pathway Genomics greatly respects and shares the FDA’s concerns about patient safety. We have received a letter from FDA, dated September 21, 2015, requesting certain information regarding the Pathway Genomics CancerIntercept™ Detect testing service. We are carefully considering the concerns of the FDA as stated in their letter, and we will be responding to that letter. We assure that there is physician involvement in the ordering, review and follow-up of CancerIntercept™ testing. We believe that CancerIntercept™ Detect is a laboratory developed test and, as a CLIA and CAP certified clinical laboratory, we are offering it as such. While Pathway Genomics is involved in educating and marketing the tests to physicians and consumers, we do not believe this is a direct-to-consumer model. We believe we have performed appropriate validation of the test as a laboratory developed test, and we are in the process of performing additional studies.

Former Administrator of the U.S. Small Business Administration Hector Barreto Joins Pathway Genomics’ Strategic Advisory Board

Hector Barreto

San Diego, CA – August 18, 2015Pathway Genomics, a global precision medical diagnostics company with mobile health applications designed to empower physicians and their patients to take control of their health and wellness, has announced today that Hector Barreto, the 21st Administrator of the U.S. Small Business Administration, has joined the Company’s Strategic Advisory Board.

Click to Tweet

Former United States Secretary of Commerce Barbara Franklin Joins Pathway Genomics’ Board of Directors

Barbara Frankin

Former United States Secretary of Commerce Barbara Franklin Joins Pathway Genomics’ Board of Directors

 

San Diego, CA – June 16, 2015Pathway Genomics Corporation, a global precision medicine company with mobile health solutions for clinical laboratory testing to empower physicians and their patients to take control of their health and wellness, announced today that the 29th U.S. Secretary of Commerce, The Honorable Barbara Franklin is joining the company’s Board of Directors.

Click to Tweet

Jim Plante, Founder and CEO of Pathway Genomics, Appointed by US Secretary of Commerce and US Trade Secretary to Industry Trade Advisory Committee (ITAC)

Jim Plante

SAN DIEGO, CA / Washington DC May 14, 2015 – Pathway Genomics Corporation, a data-driven global healthcare company and global clinical laboratory, today announced that Founder and CEO Jim Plante has been appointed by the U.S. Secretary of Commerce, Penny Pritzker, and U.S. Trade Representative (USTR), Ambassador Michael Froman to the Industry Trade Advisory Committee on Chemicals, Pharmaceuticals, Health and Science Products (ITAC 3).

Pathway Genomics Launches Updated Next Generation Sequencing Tests for Colorectal Cancer

SAN DIEGO, Mar 26, 2015 (BUSINESS WIRE) — Pathway Genomics Corporation, a forward-thinking big data healthcare company and global precision medicine clinical laboratory, announced it has launched ColoTrue™, a comprehensive panel that combines next-generation sequencing with deletion/duplication analysis to detect pathogenic variants in 15 high-risk colorectal cancer susceptibility genes. Pathway has also launched a smaller panel, LynchSyndromeTrue™, which tests for Lynch syndrome, the most common form of hereditary colon cancer.